ClinicalTrials.gg
CompletedNCT05110794Updated May 26, 2026Results posted

A Multiple-Dose Study of LY3502970 in Healthy Participants

A Phase 1 interventional study of LY3502970 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Study summary

The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in healthy participants in fed and fasted states. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study will last up to 49 days excluding the screening period.

02

Conditions studied

  • Healthy

Keywords

  • Food
  • Food Effect
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy as determined by medical evaluation.
  • Participants with body weight of 45 kilograms (kg) or more and (BMI) of 18.5 to 35.0 kilograms per meter squared (kg/m²).

Exclusion criteria

Exclusion Criteria:

  • Participants who have an abnormal blood pressure and/or pulse rate, deemed to be by the investigator at screening.
  • Participants who used or intend to use over-the-counter (OTC) or prescription medication and/or herbal/vitamin/traditional medicines or mineral supplements that may affect the safety or objectives of the study, within 14 days prior to dosing and for the duration of the study. Paracetamol and Covid-19 vaccinations are permitted.
  • Participants who are currently enrolled in a clinical study involving an product (IP) or any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Participants who show evidence of (HIV) infection and/or positive HIV antibodies. A negative test within 6 months of screening would not need to be repeated.
  • Participants who show evidence of and/or positive hepatitis C antibody. A negative test within 6 months of screening would not need to be repeated.
  • Participants who show evidence of , positive hepatitis B surface antigen, and/or positive hepatitis B core antibody. A negative test within 6 months of screening would not need to be repeated.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    LY3502970 Titration

    Dose Titration Period: Participants received increasing doses of LY3502970 administered orally every 7 days on Day 1 to Day 21. Day 1 to Day 8: 2 milligram (mg) LY3502970 every day (QD), Day 8 to Day 15: 4 mg LY3502970 QD, Day 15 to Day 21: 8 mg LY3502970 QD, Participants were randomized to Fasted state or Fed state sequence on Day 22.

    Drug: LY3502970

  • Experimental
    LY3502970 (Fasted/Fed)

    Test Period 1: Participants received 16 mg LY3502970 administered orally QD, Day 22 to Day 28 in Fasted state. Test Period 2: Participants received 16 mg LY3502970 administered orally QD, Day 29 to Day 35 in Fed state.

    Drug: LY3502970

  • Experimental
    LY3502970 (Fed/Fasted)

    Test Period 1: Participants received 16 mg LY3502970 administered orally QD, Day 22 to Day 28 in Fed state. Test Period 2: Participants received 16 mg LY3502970 administered orally QD, Day 29 to Day 35 in Fasted state.

    Drug: LY3502970

Interventions

06

What researchers measure

Primary outcomes

  1. PK: Maximum Observed Concentration (Cmax) of LY3502970

    PK: Cmax of LY3502970.

    Time frame: PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)

  2. PK: Area Under the Concentration-time Curve From 0 to 24 Hour (AUC0-24) of LY3502970

    PK: AUC0-24 of LY3502970.

    Time frame: PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)

  3. Time to Maximum Observed Concentration (Tmax) of LY3502970

    PK: Tmax of LY3502970

    Time frame: PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)

07

Results

Posted May 26, 2026

Participant flow

During the titration period, participants received increasing doses of LY3502970 administered orally every 7 days on Day 1 to Day 21. Upon completion of the titration period, participants were randomized to Fasted state or Fed state sequence of Day 22.

Titration Period
Participant flow — Titration Period
Milestone2 Milligram (mg)/4 mg/8 mg LY350297016 mg LY3502970 (Fasted/Fed)16 mg LY3502970 (Fed/Fasted)
Started3400
Received at least one dose of study drug3300
Completed2900
Not completed500
Withdrew: Adverse event500
Test Period 1
Participant flow — Test Period 1
Milestone2 Milligram (mg)/4 mg/8 mg LY350297016 mg LY3502970 (Fasted/Fed)16 mg LY3502970 (Fed/Fasted)
Started01514
Received at least one dose of study drug01514
Completed01313
Not completed021
Withdrew: Adverse event010
Withdrew: Withdrawal by subject010
Withdrew: Physician decision001
Test Period 2
Participant flow — Test Period 2
Milestone2 Milligram (mg)/4 mg/8 mg LY350297016 mg LY3502970 (Fasted/Fed)16 mg LY3502970 (Fed/Fasted)
Started01313
Received at least one dose of study drug01313
Completed01313
Not completed000

Outcome measures

PrimaryPK: Maximum Observed Concentration (Cmax) of LY3502970

PK: Cmax of LY3502970.

Time frame:
PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Maximum Observed Concentration (Cmax) of LY3502970
nanograms per milliliter (ng/mL)16 mg LY3502970 (Fasted)16 mg LY3502970 (Fed)
PK: Maximum Observed Concentration (Cmax) of LY350297080.5 ± 6467.5 ± 40
PrimaryPK: Area Under the Concentration-time Curve From 0 to 24 Hour (AUC0-24) of LY3502970

PK: AUC0-24 of LY3502970.

Time frame:
PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)
Reported as:
Geometric mean · ng*hour(h)/mL
PK: Area Under the Concentration-time Curve From 0 to 24 Hour (AUC0-24) of LY3502970
ng*hour(h)/mL16 mg LY3502970 (Fasted)16 mg LY3502970 (Fed)
PK: Area Under the Concentration-time Curve From 0 to 24 Hour (AUC0-24) of LY35029701200 ± 581050 ± 40
PrimaryTime to Maximum Observed Concentration (Tmax) of LY3502970

PK: Tmax of LY3502970

Time frame:
PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)
Reported as:
Median · hour
Time to Maximum Observed Concentration (Tmax) of LY3502970
hour16 mg LY3502970 (Fasted)16 mg LY3502970 (Fed)
Time to Maximum Observed Concentration (Tmax) of LY35029708.0 (4.00 to 16.00)8.00 (4.00 to 24.00)

Adverse events

Collected over Baseline up to Day 49. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2 Milligram (mg) LY3502970 QD0/33 (0%)0/33 (0%)27/33 (81.8%)
4 mg LY3502970 QD0/30 (0%)0/30 (0%)15/30 (50%)
8 mg LY3502970 QD0/30 (0%)0/30 (0%)13/30 (43.3%)
16 mg LY3502970 QD (Fasted)0/28 (0%)0/28 (0%)18/28 (64.3%)
16 mg LY3502970 QD (Fed)0/27 (0%)0/27 (0%)12/27 (44.4%)
Most frequent other events
Showing 10 of 32
Most frequent other events
Event2 Milligram (mg) LY3502970 QD4 mg LY3502970 QD8 mg LY3502970 QD16 mg LY3502970 QD (Fasted)16 mg LY3502970 QD (Fed)
Decreased appetiteMetabolism and nutrition disorders18/334/302/303/281/27
NauseaGastrointestinal disorders12/333/303/304/285/27
VomitingGastrointestinal disorders11/334/304/302/282/27
HeadacheNervous system disorders9/331/303/304/282/27
Abdominal distensionGastrointestinal disorders6/332/302/304/283/27
Catheter site erythemaGeneral disorders1/330/301/303/283/27
ConstipationGastrointestinal disorders1/333/301/301/280/27
Gastrooesophageal reflux diseaseGastrointestinal disorders0/333/300/300/280/27
DiarrhoeaGastrointestinal disorders2/331/302/302/282/27
Catheter site bruiseGeneral disorders0/330/300/301/282/27

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)2 mg/4 mg/8/ mg LY3502970
Mean42.8 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)2 mg/4 mg/8/ mg LY3502970
Female4
Male30
Race (NIH/OMB)
Race (NIH/OMB)(Participants)2 mg/4 mg/8/ mg LY3502970
American Indian or Alaska Native0
Asian34
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)2 mg/4 mg/8/ mg LY3502970
Singapore34
08

Study locations

1 site
  • Lilly Centre for Clinical Pharmacology
    Singapore, 138623, Singapore
09

References and documents

Publications

  • Ma X, Liu R, Pratt EJ, Benson CT, Bhattachar SN, Sloop KW. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Ther. 2024 Apr;15(4):819-832. doi: 10.1007/s13300-024-01554-1. Epub 2024 Feb 24. PubMed 38402332 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Feb 2022, 3 months.

Results were first posted in May 2026, 4 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2021
First posted
Nov 8, 2021
StartActual
Nov 5, 2021
Primary completionActual
Feb 10, 2022
CompletionActual
Feb 10, 2022
Results first posted
May 26, 2026
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05110794
Responsible party
Sponsor
First posted
Nov 8, 2021
Start date
Nov 5, 2021
Primary completion
Feb 10, 2022
Completion
Feb 10, 2022
Results posted
May 26, 2026
Last update
May 26, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion